DaVita Inc. (FRA:TRL)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.72B +13.5% |
| Revenue (ttm) | 12.26B +6.4% |
| Net Income | 741.80M +1.3% |
| EPS | 10.60 +18.7% |
| Shares Out | n/a |
| PE Ratio | 13.10 |
| Forward PE | 11.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 151.50 |
| Previous Close | 151.80 |
| Day's Range | 151.50 - 155.60 |
| 52-Week Range | 86.70 - 211.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About DaVita
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]
Financial Performance
In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.
Financial numbers in USD Financial StatementsNews
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its una...
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based ca...
DaVita flags lower revenue per treatment, reaffirms annual forecast
DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining enrollments for dialysis treatments as patients dropped out of Obamacare plans following the end of pa...
DaVita Earnings Call Transcript: Q2 2026
Second quarter results met expectations with strong volume growth from improved mortality, offset by lower commercial mix and phosphate binder revenue. Full-year guidance is reaffirmed, with continued investment in clinical innovation and capital allocation discipline.
DaVita Earnings release: Q2 2026
DaVita released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
DaVita Quarterly report: Q2 2026
DaVita has published its Q2 2026 quarterly earnings report on August 4, 2026.
DaVita Inc. 2nd Quarter 2026 Results
DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had ...
DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m...
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals
Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities. DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitme...
DaVita Transcript: Bank of America Global Healthcare Conference 2026
Volume guidance was raised due to competitor clinic closures and improved mortality, with most benefits expected by mid-year. OI growth is supported by international and value-based care, while AI and clinical innovations are being pursued for future efficiency and patient outcomes.
DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference
DENVER, May 6, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will parti...
DaVita lifts annual profit forecast on strong demand for dialysis services
DaVita on Tuesday raised its forecast for annual adjusted profit after beating Wall Street estimates for first-quarter results, betting on steady demand for its kidney dialysis services.
DaVita Earnings Call Transcript: Q1 2026
First quarter results exceeded expectations, driven by higher treatment volume, improved productivity, and technology investments. Guidance for adjusted operating income and EPS was raised, with additional volume growth expected from competitor clinic closures.
DaVita Earnings release: Q1 2026
DaVita released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
DaVita Quarterly report: Q1 2026
DaVita has published its Q1 2026 quarterly earnings report on May 5, 2026.
DaVita Inc. 1st Quarter 2026 Results
DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2026. "DaVita's foundation is clinical excellence, driven by opera...
Honeywell Announces Board of Directors for Honeywell Aerospace
Directors bring compelling mix of aerospace and defense expertise, leadership experience, and financial and capital markets backgrounds Honeywell spin-off of Honeywell Aerospace expected to be complet...
DaVita Proxy statement: Proxy filing
DaVita filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
DaVita Proxy statement: Proxy filing
DaVita filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call
DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. E...
DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy an...
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global dev...
DaVita Transcript: TD Cowen 46th Annual Health Care Conference
2026 OI growth is projected above the low end of long-term targets, driven by U.S. dialysis, international, and IKC segments. Margin maintenance, cost controls, and IT investments are key, while APTC expiration and clinical programs will shape future mix and volume. Double-digit EPS growth and disciplined capital deployment remain priorities.
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
DENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will par...
